title: Oral delivery of anticancer drugs II: the prodrug strategy.
abstract: Many anticancer drugs are sparingly water soluble and they show a low permeability at the intestinal level. Furthermore, their oral bioavailability is impaired because they are substrates of the cytochrome P450 and of the efflux pumps. The prodrug strategy, which is discussed in the present review, represents one of the different approaches to overcome these obstacles. In this review, we highlight the progresses of clinical development in the prodrug area for the oral administration of anticancer drugs.
authors.affiliation: Université Paris-Sud, Faculté de Pharmacie, UMR CNRS 8612, Institut Galien Paris-Sud, 5, rue JB Clément, 92296 Châtenay-Malabry Cedex, France.
authors.forename: Silvia
authors.initials: S
authors.lastname: Mazzaferro
authors.forename: Kawthar
authors.initials: K
authors.lastname: Bouchemal
authors.forename: Gilles
authors.initials: G
authors.lastname: Ponchel
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001682:Biological Availability; D015195:Drug Design; D006801:Humans; D007408:Intestinal Absorption; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010539:Permeability; D011355:Prodrugs; D012995:Solubility
chemical_list: D000970:Antineoplastic Agents; D011355:Prodrugs